Autor(es): Jublot, Delphine ; Cavaillès, Pierre ; Kamche, Salima ; Francisco, Denise ; Fontinha, Diana ; Prudêncio, Miguel ; Guichou, Jean-Francois ; Labesse, Gilles ; Sereno, Denis ; Loeuillet, Corinne
Data: 2022
Identificador Persistente: http://hdl.handle.net/10451/52079
Origem: Repositório da Universidade de Lisboa
Assunto(s): HDACi; IC50; Plasmodium; Anti-Toxoplasma drug; Mice; Treatment
Toxoplasmosis is a highly prevalent human disease, and virulent strains of this parasite emerge from wild biotopes. Here, we report on the potential of a histone deacetylase (HDAC) inhibitor we previously synthesized, named JF363, to act in vitro against a large panel of Toxoplasma strains, as well as against the liver and blood stages of Plasmodium parasites, the causative agents of malaria. In vivo administration of the drug significantly increases the survival of mice during the acute phase of infection by T. gondii, thus delaying its spreading. We further provide evidence of the compound's efficiency in controlling the formation of cysts in the brain of T. gondii-infected mice. A convincing docking of the JF363 compound in the active site of the five annotated ME49 T. gondii HDACs was performed by extensive sequence-structure comparison modeling. The resulting complexes show a similar mode of binding in the five paralogous structures and a quite similar prediction of affinities in the micromolar range. Altogether, these results pave the way for further development of this compound to treat acute and chronic toxoplasmosis. It also shows promise for the future development of anti-Plasmodium therapeutic interventions.
